Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center (BIDMC) was founded at the turn of the century. Like Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH), it is a full-service Harvard teaching hospital with about 500 beds and a full array of cancer care activities. It also maintains, jointly with Harvard Medical School (HMS), a foundation for the purpose of maximizing the quality of clinical medical education, including the teaching of cancer medicine. In addition to its intense and abiding interest in a wide spectrum of clinical cancer research, it is a center of excellence in angiogenesis research, cancer cell biology, molecular signaling, and prostate cancer biology. Like MGH and BWH, its senior faculty have contributed in major ways to the planning of the Center, and BIDMC senior leaders are also members of DF/HCC leadership. Kevin Tabb, MD, President and CEO of the Hospital, sits on the DF/HCC Governance Committee. Lewis Cantley, PhD serves as Cancer Center Director, Dr Pier Paolo Pandolfi is Co Director for Basic Research, Dr. Lowell Schnipper, is Co-Director for Clinical Programs and Services, serves as Associate Director for Membership.